Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy, according to results of follow-up animal studies performed after the conclusion of a recent clinical trial in humans.
Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy, according to results of follow-up animal studies performed after the conclusion of a recent clinical trial in humans.